dc.creator | Rivero-Juárez, Antonio | es |
dc.creator | López Cortés, Luis Fernando | es |
dc.creator | Camacho, Ángela | es |
dc.creator | Torres Cornejo, Almudena | es |
dc.creator | Pineda Vergara, Juan Antonio | es |
dc.creator | Márquez-Solero, Manuel | es |
dc.creator | Rivero, Antonio | es |
dc.date.accessioned | 2021-07-02T14:46:18Z | |
dc.date.available | 2021-07-02T14:46:18Z | |
dc.date.issued | 2012-11-08 | |
dc.identifier.citation | Rivero-Juárez, A., López Cortés, L.F., Camacho, Á., Torres Cornejo, A., Pineda Vergara, J.A., Márquez-Solero, M. y Rivero, A. (2012). Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. PLoS ONE, 7 (11), art. n.48959. | |
dc.identifier.issn | 1932-6203 (electrónico) | es |
dc.identifier.uri | https://hdl.handle.net/11441/115068 | |
dc.description.abstract | Background: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-a2a/RBV therapies
on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment.
Methods: Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naı¨ve
HCV genotype 3 patients with HIV co-infection. The Standard Dose Group (SDG) included patients who received Peg-IFN at
180 mg/per week with a weight-adjusted dose of ribavirin; Low-Dose Group (LDG) patients received Peg-IFN at 135 mg/per
week with 800 mg/day ribavirin. The effect of IL28B genotype on HCV viral decline was evaluated in both groups. HCV viral
decline was analyzed using a multivariate linear regression model.
Results: One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for
patients in the LDG was less than for those in the SDG (week 1:1.7260.74 log10 IU/mL versus 1.7860.67 log10 IU/mL,
p = 0.827; week 2:2.360.89 log10 IU/mL versus 3.0161.02 log10 IU/mL, p = 0.013; week 4:3.5261.2 log10 IU/mL versus
4.0961.1 log10 IU/mL, p = 0.005). The linear regression model identified the Peg-IFN/RBV dose as an independent factor for
HCV viral decline at week 4.
Conclusions: Our results showed that HCV viral decline was less for patients in the low-dose group compared to those
receiving the standard dose. Until a randomized clinical trial is conducted, clinicians should be cautious about using lower
doses of Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients. | es |
dc.description.sponsorship | Fundación Progreso y Salud, Consejería de Salud de la Junta de Andalucía (refs. 0036/2010, PI-0247-2010 and PI-0208 and 0124/2008 | es |
dc.description.sponsorship | Spanish Health Ministry (ISCIII-RETIC RD06/006, and projects PI10/0164 and PI10/01232) | es |
dc.description.sponsorship | Fundación Progreso y Salud, Consejería de Salud de la Junta de Andalucía (Reference AI0011-2010) | es |
dc.description.sponsorship | Instituto de Salud Carlos III (grant number Programa-I3SNS) | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Public Library of Science | es |
dc.relation.ispartof | PLoS ONE, 7 (11), art. n.48959. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Low-Dose Group | es |
dc.subject | HCV Viral | es |
dc.subject | Standard Dose Group | es |
dc.subject | Peg-IFN/RBV treatment | es |
dc.title | Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | 0036/2010 | es |
dc.relation.projectID | PI-0247-2010 | es |
dc.relation.projectID | PI-0208 | es |
dc.relation.projectID | 0124/2008 | es |
dc.relation.projectID | ISCIII-RETIC RD06/006 | es |
dc.relation.projectID | PI10/0164 | es |
dc.relation.projectID | PI10/01232 | es |
dc.relation.projectID | Reference AI0011-2010 | es |
dc.relation.projectID | Programa-I3SNS | es |
dc.relation.publisherversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048959 | es |
dc.identifier.doi | 10.1371/journal.pone.0048959 | es |
dc.journaltitle | PLoS ONE | es |
dc.publication.volumen | 7 | es |
dc.publication.issue | 11 | es |
dc.publication.initialPage | art. n.48959 | es |